Human Immunodeficiency Virus Status, Tenofovir Exposure, and the Risk of Poor Coronavirus Disease 19 Outcomes: Real-World Analysis From 6 United States Cohorts Before Vaccine Rollout.

BACKGROUND

People with human immunodeficiency virus (HIV) (PWH) may be at increased risk for severe coronavirus disease 2019 (COVID-19) outcomes. We examined HIV status and COVID-19 severity, and whether tenofovir, used by PWH for HIV treatment and people without HIV (PWoH) for HIV prevention, was associated with protection.

METHODS

Within 6 cohorts of PWH and PWoH in the United States, we compared the 90-day risk of any hospitalization, COVID-19 hospitalization, and mechanical ventilation or death by HIV status and by prior exposure to tenofovir, among those with severe acute respiratory syndrome coronavirus 2 infection between 1 March and 30 November 2020. Adjusted risk ratios (aRRs) were estimated by targeted maximum likelihood estimation, with adjustment for demographics, cohort, smoking, body mass index, Charlson comorbidity index, calendar period of first infection, and CD4 cell counts and HIV RNA levels (in PWH only).

RESULTS

Among PWH (n = 1785), 15% were hospitalized for COVID-19 and 5% received mechanical ventilation or died, compared with 6% and 2%, respectively, for PWoH (n = 189 351). Outcome prevalence was lower for PWH and PWoH with prior tenofovir use. In adjusted analyses, PWH were at increased risk compared with PWoH for any hospitalization (aRR, 1.31 [95% confidence interval, 1.20-1.44]), COVID-19 hospitalizations (1.29 [1.15-1.45]), and mechanical ventilation or death (1.51 [1.19-1.92]). Prior tenofovir use was associated with reduced hospitalizations among PWH (aRR, 0.85 [95% confidence interval, .73-.99]) and PWoH (0.71 [.62-.81]).

CONCLUSIONS

Before COVID-19 vaccine availability, PWH were at greater risk for severe outcomes than PWoH. Tenofovir was associated with a significant reduction in clinical events for both PWH and PWoH.

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: [e-mail].

Déclaration de conflit d'intérêts

Potential conflicts of interest. V. C. M. has received investigator-initiated research grants (to the institution) and consultation fees, both unrelated to the current work, from Eli Lilly, Bayer, Gilead Sciences, and ViiV; research grants from the NIH, the Centers for Disease Control and Prevention, and the Department of Veterans Affairs; payment or honoraria for speaking from Medscape/WebMD/ViiV; and writing honoraria from Integritas and Lilly. V. C. M. also reports participation on a data and safety monitoring board study section for the NIH. K. N. A. has received investigator-initiated research grants from the NIH (to the institution) and consultation fees (both unrelated to the current work) from the All of Us Research Program (NIH; payment to the author), TrioHealth (payment to the author as advisory board member), and Kennedy Dundas; K. N. A. also reports royalties or licenses from Coursera as the director of a 5-course specialization (payment to the author and institution). K. A. G. has received consulting fees, unrelated to the current work, from Teach for America, the Aspen Institute, and UptoDate. K. A. G. also reports grants to the institution from Octapharma, the US Department of Defense's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, the National Institute of Allergy and Infectious Diseases, NIH (grant 3R01AI152078-01S1), the NIH National Center for Advancing Translational Sciences (grants U24TR001609-S3 and UL1TR00309), the Mental Wellness Foundation, HealthNetwork Foundation, Bloomberg Philanthropies, Moriah Fund, the Shear Family Foundation, the State of Maryland, and the Defense Health Agency (grant W911QY2090012); royalties or licenses to the author from UpToDate; consulting fees to the author from Spark Healthcare, Aspen Institute, and Teach for America; and unpaid consultation to Pfizer for Scientific Advisory Board. R. L. reports grants or contracts paid to the institution from University of Calgary. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.